Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the Corbevax™ vaccine that recently received emergency use authorization by the Drugs Controller General of India. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum+CpG. We also evaluated mice immunized with RBD/alum+CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum+CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B. 1.351 (Beta), B. 1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum+CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2 including variants of concern.

[1]  G. Medigeshi,et al.  Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies , 2022, medRxiv.

[2]  Gregory D. Gromowski,et al.  A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates , 2021, Science Translational Medicine.

[3]  Gregory D. Gromowski,et al.  A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge , 2021, NPJ vaccines.

[4]  G. Screaton,et al.  The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies , 2021, bioRxiv.

[5]  P. Hotez,et al.  Restoring Vaccine Diplomacy. , 2021, JAMA.

[6]  Gregory D. Gromowski,et al.  SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity , 2021, bioRxiv.

[7]  M. Nussenzweig,et al.  Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection , 2021, bioRxiv.

[8]  B. Pulendran,et al.  Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.

[9]  P. Hotez,et al.  SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice , 2021, Human vaccines & immunotherapeutics.

[10]  D. Ho,et al.  Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques , 2021, bioRxiv.

[11]  L. Stamatatos,et al.  mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.

[12]  Yan Liu,et al.  Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.

[13]  K. Makar,et al.  WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.

[14]  M. Nussenzweig,et al.  Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice , 2020, Science.

[15]  P. Hotez,et al.  Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1 , 2020, Applied Microbiology and Biotechnology.

[16]  J. Pollet,et al.  Recombinant protein vaccines, a proven approach against coronavirus pandemics , 2020, Advanced Drug Delivery Reviews.

[17]  P. Hotez,et al.  Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate , 2020, Biochimica et Biophysica Acta (BBA) - General Subjects.

[18]  R. Owens,et al.  A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses , 2020, Nature Communications.

[19]  P. Hotez,et al.  Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement , 2020, bioRxiv.

[20]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[21]  Kevin S. Naceanceno,et al.  Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen , 2018, Vaccine.

[22]  P. Hotez,et al.  New Vaccines for the World's Poorest People. , 2016, Annual review of medicine.

[23]  D. Klinman,et al.  Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. , 2014, Vaccine.

[24]  A. Jakubowska,et al.  CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice , 2004, Clinical Cancer Research.

[25]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[26]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[27]  D. Klinman,et al.  CpG Oligonucleotides as Vaccine Adjuvants. , 2021, Methods in molecular biology.

[28]  A. Sigal,et al.  Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021 .

[29]  John D Campbell,et al.  Development of the CpG Adjuvant 1018: A Case Study. , 2017, Methods in molecular biology.

[30]  Xavier le Guezennec,et al.  Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants. , 2017, Journal of immunological methods.